Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Price Target at $29.88

Posted by Stanley Muller on May 21st, 2026

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $29.8750.

A number of brokerages recently issued reports on FDMT. Jefferies Financial Group reiterated a “buy” rating and issued a $21.00 price target (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Monday, March 30th. Barclays began coverage on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 28th. They issued an “overweight” rating and a $33.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Chardan Capital reiterated a “buy” rating and issued a $26.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th. Finally, Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th.

Check Out Our Latest Stock Analysis on 4D Molecular Therapeutics

4D Molecular Therapeutics Price Performance

Shares of 4D Molecular Therapeutics stock opened at $8.47 on Friday. The stock has a market cap of $442.78 million, a price-to-earnings ratio of -3.30 and a beta of 2.77. The firm’s 50-day moving average is $9.46 and its 200 day moving average is $9.38. 4D Molecular Therapeutics has a 1 year low of $3.37 and a 1 year high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The firm had revenue of $3.05 million during the quarter, compared to the consensus estimate of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. On average, equities analysts expect that 4D Molecular Therapeutics will post -3.77 EPS for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Dynamic Technology Lab Private Ltd bought a new position in 4D Molecular Therapeutics during the 1st quarter valued at about $39,000. Wexford Capital LP bought a new position in 4D Molecular Therapeutics during the 3rd quarter valued at about $41,000. AQR Capital Management LLC bought a new position in 4D Molecular Therapeutics during the 1st quarter valued at about $46,000. Daiwa Securities Group Inc. lifted its stake in 4D Molecular Therapeutics by 3,362.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock valued at $48,000 after acquiring an additional 6,186 shares during the period. Finally, Rangeley Capital LLC bought a new position in 4D Molecular Therapeutics during the 2nd quarter valued at about $48,000. Institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

(Get Free Report)

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.